EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

American Journal of Surgical Pathology

Volumn 29, Issue 5, 2005, Pages 633-639

  Yatabe, Yasushi ^a   Kosaka, Takayuki ^a   Takahashi, Takashi ^a   Mitsudomi, Tetsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Atypical adenomatous hyperplasia; Bronchioloalveolar features; EGFR mutation; Gefitinib; Lung adenocarcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; K RAS PROTEIN; LUNG SURFACTANT; PROTEIN P53; RNA; SURFACTANT PROTEIN B; THYROID TRANSCRIPTION FACTOR 1;

ADENOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; BRONCHUS MUCOSA; CELL STRUCTURE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; LUNG ADENOCARCINOMA; LUNG ALVEOLUS; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRECANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; TERMINAL RESPIRATORY UNIT ADENOCARCINOMA; TISSUE MICROARRAY;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GLYCOPROTEINS; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MUTATION; PROTEIN ARRAY ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 17744371335     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000157935.28066.35     Document Type: Article

References (57)

1. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92;1525-1530.
2. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30:3-14.
3. Arteaga CL, Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. 2002;29:3-9.
4. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001;98:13790-13795.
5. Carraway KL, Carraway CAC. Signalling by tyrosine kinases, In: Alison M, ed. The Cancer Handbook. London: Nature, 2002:161-177.
6. Cassel TN, Suske G, Nord M. C/EBP alpha and TTF-1 synergistically transactivate the Clara cell secretory protein gene. Ann N Y Acad Sci. 2000:923:300-302.
7. Clayton F. The spectrum and significance of bronchioloalveolar carcinomas. Pathol Annu. 1988;23:361-394.
8. Edwards CW. Pulmonary adenocarcinoma: review of 106 cases and proposed new classification. J Clin Pathol. 1987;40:125-135.
9. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485.
10. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237-2246.
11. Fukuyama Y, Mitsudomi T, Sugio K., et al. K-cas and p53 munitions are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer. 1997;75:1125-1130.
12. Garber MH, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 2001; 98:13784-13789.
13. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell King cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
14. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
15. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004;22:785-794.
16. Herrera G, Alexander B. Ultrastructural subtypes of pulmonary adenocarcinoma: a correlation with patient survival. Chest. 1983;84:581-586.
17. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
18. Ishioka C, Frebourg T, Yan YX, et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet. 1993;5:124-129.
19. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31-53.
20. Kimula Y. A histological and ultrastructural study of adenocarcinoma of the lung. Am J Surg Pathol. 1978;2:253-264.
21. Kimura S, Hara Y, Pineau T, et al. The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996;10:60-69.
22. Kitamura Y, Hirota S, Nishida T. Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci. 2003;94:315-320.
23. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factors receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919-8923.
24. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290:2149-2158.
25. Kurokawa T, Matsuno Y, Noguchi M, et al. Surgically curable 'early' adenocarcinoma in the periphery of the lung. Am J Surg Pathol. 1994;18: 431-438.
26. Lee JW, Soung YH, Kim SY, et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer. 2005;113:510-511.
27. Linnoila RI, Jensen SM, Steinberg SM, et al. Peripheral airway cell marker expression in non-small cell lung carcinoma: association with distinct clinicopathologic features. Am J Clin Pathol. 1992;97:233-243.
28. Linnoila RI, Mulshine JL, Steinberg SM, et al. Expression of surfactant-associated protein in non-small-cell lung cancer: a discriminant between biologic subsets. J Natl Cancer Inst Monogr. 1992;13:61-66.
29. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
30. Mendelsohn J, Baird A, Fan Z, et al. Growth factors and their receptors in epithelial malignancies. In: Mendelsohn J, Howley PM, Israel MA, et al, eds. The Molecular Basis of Cancer, 2nd ed. Philadelphia: Saunders, 2001:137-161.
31. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103-1109.
32. Minoo P, Su G, Drum H, et al. Defects in tracheoesophageal and lung morphogenesis in Nkx2.1(-/-) mouse embryos. Dev Biol. 1999;209: 60-71.
33. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787-1790.
34. Nord M, Cassel TN, Braun H, et al. Regulation of the Clara cell secretory protein/uteroglobin promoter in lung. Ann N Y Acad Sci. 2000;923:154-165.
35. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304: 1497-1500.
36. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
37. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
38. Simosato Y. Lung tumors. In: Sternberg SS, ed. Diagnostic Surgical Pathology, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999.
39. Singh G, Katyal SL, Torikata C. Carcinoma of type II pneumocytes: immunodiagnosis of a subtype of 'bronchioloalveolar carcinomas.' Am J Pathol. 1981;102:195-208.
40. Singh G, Katyal SL, Torikata C. Carcinoma of type II pneumocytes: PAS staining as a screening test for nuclear inclusions of surfactant specific apoprotein. Cancer. 1982;50:946-948.
41. Singh G, Scheithauer BW, Katyal SL. The pathobiologic features of carcinomas of type II pneumocytes: an immunocytologic study. Cancer. 1986;57:994-999.
42. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305:1163-1167.
43. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
44. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
45. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393-10398.
46. Stewart BW, Kleichues P, eds. World Cancer Report. Lyon, France: IARC Press, 2003.
47. Tomida S, Koshikawa K, Yatabe Y, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene. 2004;23:6360-6370.
48. Travis WD, Brambilla E, et al, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.
49. Troester MA, Hoadley KA, Sorlie T, et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004;64:4218-4226.
50. Wang ZC, Lin M, Wei LJ, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004;64:64-71.
51. Waridel F, Estreicher A, Bron L, et al. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene. 1997;14:163-169.
52. Whitsett JA, Classer SW. Regulation of surfactant protein gene transcription. Biochim Biophys Acta. 1998;1408:303-311.
53. Yatabe Y, Konishi H, Mitsudomi T, et al. Topographical distributions of allelic loss in individual non-small-cell lung cancers. Am J Pathol. 2000; 157:985-993.
54. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002;26:767-773.
55. Yatabe Y. Role of expression of Thyroid transcription factor-1 in pulmonary adenocarcinoma. In: Hayat MA, ed. Immunohistochemistry and In Situ Hybridization of Human Carcinomas. New York: Elsevier Science/Academic Press, 2004:169-179.
56. Yatabe Y, Koga T, Mitsudomi T, et al. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol. 2004;203:645-652.
57. Yatabe Y, Mitsudomi T, Takahashi T. Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene. 2004;23: 4041-4049.